Skip to main content

Table 2 Quality of Life, Medication Satisfaction, and Tolerability Scores

From: Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients

Quality of life instruments

Baseline

Change from baseline to week 4

Change from baseline to week 12

 

Mean (SD)

Mean (SD)

P-value

Mean (SD)

P-value

*Physical health summary score (PHS)

48.2 (11.5)

0.015 ± 9.00

0.97

0.315 ± 9.20

0.79

*Mental health summary score (MHS)

50.7 (12.0)

0.366 ± 9.07

0.74

0.313 ± 10.01

0.81

*Augmented symptom distress module (ASDM)

26.7 (19.8)

-2.99 ± 16.34

0.14

-2.92 ± 16.48

0.17

*Center for Epidemiology Studies-Depression (CES-D)

14.5 (10.2)

-1.12 ± 8.00

0.25

-0.753 ± 8.47

0.49

  

Mean value at week 4

Mean value at week 12

Medication satisfaction survey (MSS)

 

9.01 ± 2.27

NA

8.69 ± 2.25

NA

Global Condition improvement (GCI)

 

2.24 ± 3.05

<0.0001

2.46 ± 3.30

<0.0001

Therapy preference

     

   Prefer LPV/r tablet [No. (%)]

 

55 (78%)

<0.0001

46 (74%)

<0.0001

   Prefer LPV/r SGC [No. (%)]

 

6 (9%)

 

6 (10%)

 

   No preference [No. (%)]

 

9 (13%)

 

10 (16%)

 
  1. *These instruments were scored according to the published scoring algorithm [46]; SD, standard deviation; SGC, soft gel capsule; LPV/r, lopinavir/ritonavir;